• Explore /
  • Poster
  • / Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Phase 1/2 randomized, open-label, multicenter, Simon two-stage study of pelareorep combined with modified FOLFIRINOX +/- atezolizumab in patients with metastatic pancreatic ductal adenocarcinoma.

Abstract Poster

Authors

Dirk Arnold

Dirk Arnold

Department of Oncology, AK Altona, Asklepios Tumourzentrum Hamburg, Hamburg, Germany

Dirk Arnold , Houra Loghmani , Karol Cheetham , Richard Trauger , Thomas Charles Heineman

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Advanced/Metastatic Disease

Clinical Trial Registration Number

Eudra-CT: 2020-003996-16

Citation

J Clin Oncol 42, 2024 (suppl 16; abstr TPS4203)

DOI

10.1200/JCO.2024.42.16_suppl.TPS4203

Abstract #

TPS4203

Poster Bd #

171b

Abstract Disclosures

Similar Posters

First Author: Philipp Harter

First Author: Dirk Arnold

First Author: Andre Rashad Kydd

First Author: Dong Ho Lee